tetano
Editor, Senior Moderator
J Thromb Thrombolysis
. 2021 Apr 28.
doi: 10.1007/s11239-021-02447-x. Online ahead of print.
Massive intraperitoneal hemorrhage in patients with COVID-19: a case series
Vahid Reisi-Vanani[SUP] 1 [/SUP], Zahra Lorigooini[SUP] 2 [/SUP], Mohamad Ali Dayani[SUP] 3 [/SUP], Mehrandokht Mardani[SUP] 4 [/SUP], Fereidoun Rahmani[SUP] 5 [/SUP]
Affiliations
Abstract
Coronavirus disease (COVID-19) initiates several life-threatening complications including coagulopathies with a unique characteristic that made this problem challenging. Here we presented 4 cases of RT-PCR positive patients that have experienced deadly intraperitoneal hemorrhage with fourth WHO Bleeding Grade after overcoming their respiratory phase. COVID-19 could induce several coagulopathies with different features that besides iatrogenic interventions increases its mortality and morbidity due to lack of clinical evidence based on well-designed randomized clinical trials on anticoagulation therapies (AT) and administration of varieties of newly approved and non-approved medicines. This report showed the urgent need for investigation on the pathophysiology of COVID-19-associated coagulopathy esp. in hemorrhagic events which are needed to make the best therapeutic decision.
Keywords: COVID-19; Coagulopathy; Disseminated intravascular coagulation; Thrombotic microangiopathy.
. 2021 Apr 28.
doi: 10.1007/s11239-021-02447-x. Online ahead of print.
Massive intraperitoneal hemorrhage in patients with COVID-19: a case series
Vahid Reisi-Vanani[SUP] 1 [/SUP], Zahra Lorigooini[SUP] 2 [/SUP], Mohamad Ali Dayani[SUP] 3 [/SUP], Mehrandokht Mardani[SUP] 4 [/SUP], Fereidoun Rahmani[SUP] 5 [/SUP]
Affiliations
- PMID: 33909261
- DOI: 10.1007/s11239-021-02447-x
Abstract
Coronavirus disease (COVID-19) initiates several life-threatening complications including coagulopathies with a unique characteristic that made this problem challenging. Here we presented 4 cases of RT-PCR positive patients that have experienced deadly intraperitoneal hemorrhage with fourth WHO Bleeding Grade after overcoming their respiratory phase. COVID-19 could induce several coagulopathies with different features that besides iatrogenic interventions increases its mortality and morbidity due to lack of clinical evidence based on well-designed randomized clinical trials on anticoagulation therapies (AT) and administration of varieties of newly approved and non-approved medicines. This report showed the urgent need for investigation on the pathophysiology of COVID-19-associated coagulopathy esp. in hemorrhagic events which are needed to make the best therapeutic decision.
Keywords: COVID-19; Coagulopathy; Disseminated intravascular coagulation; Thrombotic microangiopathy.